A Phase 3 interventional study of LP-003 and Placebo in Seasonal Allergic Rhinitis, sponsored by Longbio Pharma. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Longbio Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 6th largest by enrollment, is one of 3 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 2 of the 13 other live ones, and was the 21st registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
Chengdu Kangnuoxing Biopharma,Inc. · Sites in China
Ages 12–18
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Sites in China
Ages 18–75
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Shanghai Mabgeek Biotech.Co.Ltd · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 11
First in 2017; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 546 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 160 across the 27 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
Longbio Pharma is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Longbio Pharma has 2 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
5 of the studies in Rhinitis, Allergic, Seasonal with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07688772Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07678931Phase 3Chengdu Kangnuoxing Biopharma,Inc.Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07199257Phase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | 2027-05-15 |
| NCT07711262Phase 3Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | 2027-10 |
| NCT07398859Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | 2026-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of LP-003 injection in patients with moderate to severe seasonal allergic rhinitis inadequately controlled by standard-of-care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received subcutaneous of LP-003 Injection at a dose of 100 mg once every 4 weeks.
Biological: LP-003
Participants received subcutaneous of Placebo Injection once every 4 weeks.
Biological: Placebo
Participants were administered LP-003 via subcutaneous injection every 4 weeks.
Participants were administered Placebo via subcutaneous injection every 4 weeks
Mean daily reflective total nasal symptom score (rTNSS) during the pollen peak period (PPP)
The rTNSS is a patient self-reported questionnaire of four nasal symptoms: nasal itching, nasal congestion, sneezing and rhinorrhea. Patients will report their symptoms reflected or felt over the last 12 hours. Each symptom is scored on a 0-3 scale (0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe). The total score is the sum of the four items, ranging from 0 to 12, with higher scores indicating greater symptom severity.
Time frame: Up to 4 Months
Mean daily rTNSS during the pollen period (PP)
Time frame: Up to 4 Months
Mean daily instantaneous total nasal symptom score (iTNSS) during the PPP
Time frame: Up to 4 Months
Mean daily iTNSS during the PP
Time frame: Up to 4 Months
Mean daily rTNSS combined with rescue medication score (DNSMS) during the PPP
Integrates daily rTNSS (4 nasal symptoms, 0-3 each, total 0-12) and rescue medication score (0 for no rescue use and 1 for rescue use).
Time frame: Up to 4 Months
Mean daily total ocular symptom score (TOSS) during the PPP
It is derived from 2 individual ocular symptoms (itching/burning/redness, and tearing/watering), and each symptom is scored on a 0-3 scale. The daily TOSS is the sum of the two items, ranging from 0 (no symptoms) to 6 (maximum severity) per day.
Time frame: Up to 4 Months
Mean daily TOSS combined with rescue medication score (DNOMS) during the PPP
Integrates daily TOSS (2 individual ocular symptoms, 0-3 each, total 0-6) and rescue medication score (0 for no rescue use and 1 for rescue use).
Time frame: Up to 4 Months
Mean daily rescue medication score (RMS) during the PPP
The RSM is assessed based on the usage of montelukast sodium tablets, with a scoring rule of 0 points for no use and 1 point for use on the day. The mean daily RSM during the PPP is calculated as the sum of the cumulative RSM during the PPP divided by the number of days in the PPP.
Time frame: Up to 4 Months
Incidence of adverse events (AEs)
Time frame: Up to Week 28
Started Aug 2024 (actual). Primary completion is estimated for Mar 2026, 19 months after the start.
Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's planned 19 months is above that.
Counting every sponsor, half of 37 studies reached it within 4 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LP-003
Rhinitis, Allergic, Seasonal →
Longbio Pharma